Results 1 to 10 of about 47,032 (177)
Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents
Pharmaceuticals, 2021 Radiolabeled fluorescent dyes are decisive for bimodal imaging as well as highly in demand for nuclear- and optical imaging. Silicon-rhodamines (SiRs) show unique near-infrared (NIR) optical properties, large quantum yields and extinction coefficients as
Thines Kanagasundaram +6 more
doaj +1 more source
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy
Journal of Nuclear Medicine, 2023 Visual Abstract Auger electron (AE) radiopharmaceutical therapy (RPT) may have the same therapeutic efficacy as α-particles for oncologic small disease, with lower risks of normal-tissue toxicity.
Julie Bolcaen +8 more
semanticscholar +1 more source
EJNMMI Radiopharmacy and Chemistry, 2023 Background [18F]fluoromisonidazole ([18F]FMISO, 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole) is a commonly used radiotracer for imaging hypoxic conditions in cells.
Torsten Kniess +5 more
doaj +1 more source
CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells
Cells, 2022 The inducible isoenzyme cyclooxygenase-2 (COX-2) is an important hub in cellular signaling, which contributes to tumor progression by modulating and enhancing a pro-inflammatory tumor microenvironment, tumor growth, apoptosis resistance, angiogenesis and
Cathleen Haase-Kohn +4 more
doaj +1 more source
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Seminars in nuclear medicine, 2023 Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease.
S. Alati +4 more
semanticscholar +1 more source
Dosimetry in Radiopharmaceutical Therapy
Journal of Nuclear Medicine, 2022 The application of radiopharmaceutical therapy for the treatment of certain diseases is well established, and the field is expanding. New therapeutic radiopharmaceuticals have been developed in recent years, and more are in the research pipeline ...
Joe O’Donoghue +3 more
semanticscholar +1 more source
Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
Frontiers in Chemistry, 2023 177Lu is a radioisotope that has become increasingly popular as a therapeutic agent for treating various conditions, including neuroendocrine tumors and metastatic prostate cancer.
Siju C. George +5 more
semanticscholar +1 more source
Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry
Molecules, 2023 The β− emitter, rhenium-188 (188Re), has long been recognized as an attractive candidate for targeted cancer radionuclide therapy (TRNT). This transition metal shares chemical similarities with its congener element technetium, whose nuclear isomer ...
J. Kleynhans, A. Duatti, C. Bolzati
semanticscholar +1 more source
Molecules, 2022 COX-2 can be considered as a clinically relevant molecular target for adjuvant, in particular radiosensitizing treatments. In this regard, using selective COX-2 inhibitors, e.g., in combination with radiotherapy or endoradiotherapy, represents an ...
Florian Brandt +7 more
doaj +1 more source
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Pharmaceuticals, 2021 For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in
Ute Hennrich, M. Eder
semanticscholar +1 more source